Zevra TherapeuticsZVRA
Recorded

Zevra Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration42 minParticipants12

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon, and thank you for joining Zevra's third quarter 2026 financial results and corp. Today's call is being recorded and will be available via the investor relations section of the company's website later today. The host for today's call is Nichol Ochsner, Zevra's Vice President of Investor Relations and Corporate Communications.

Nichol OchsnerVP of Investor Relations and Corporate Communications

Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our third quarter 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the investor section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by any forward-looking statements due to risks and uncertainties associated with Zevra's business.

Nichol OchsnerVP of Investor Relations and Corporate Communications

Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties, and other important factors that may lead to actual results differing materially from the projections made, and should be evaluated together with the risk factor section in our most recent quarterly report on Form 10-Q or annual report on Form 10-K and our other filings with the SEC. I am pleased to welcome Zevra's management team members participating in today's call: Neil McFarlane, Zevra's President and Chief Executive Officer, Josh Schafer, our Chief Commercial Officer, and Justin Renz, our Chief Financial Officer. Now, it is my pleasure to hand the call over to Neil.

Neil McFarlanePresident and CEO

Thank you, Nicole, and welcome to everyone joining our quarterly call this afternoon. Zevra is a purpose-driven company, redefining what is possible and bringing life-changing therapies to people living with rare diseases. In rare disease, the path is complex, the needs are urgent, and the responsibility is significant. The people and families behind these needs at the heart of what we do every day. Progress with the U.S. launch of MIPLYFFA, the first approved therapy for Niemann-Pick disease type C, or NPC, reflects the disciplined execution of our strategic plan and the determination, expertise, and commitment of our people. Together, we are building a trusted company with the capabilities and resolve to make a lasting difference. I am pleased to share that total net revenue for the third quarter was $37.8 million, an increase of 45% compared to the third quarter of 2025.

Neil McFarlanePresident and CEO

Net U.S. product revenue for MIPLYFFA was $34 million. What we are seeing in the market suggests that it may be just the beginning, particularly as we strengthen our understanding of the NPC community in the United States, where an estimated 900 people are living with NPC, of whom 300 to 350 have been diagnosed. These estimates are derived from a study published in 2021, prior to any approved treatment for NPC. in the third quarter, we received 13 prescriptions, cumulative since launch to 197. In rare disease, the number of identified patients often grows over time as awareness increases, more patients receive a diagnosis, and new therapies are approved. Josh will share more details on how our initiatives are driving patient identification, diagnosis, and treatment later in the call.

Neil McFarlanePresident and CEO

Our commitment to realizing MIPLYFFA's full potential and supporting the NPC community is driving our investment to expand patient access. In the second quarter, we published data from a multicenter, open-label pediatric substudy evaluating treatment of NPC with arimoclomol in combination with miglustat in infants six months to less than 24 months of age. The substudy assessed safety and tolerability for up to 36 months of treatment and found that arimoclomol was well tolerated with no new observed safety signals. On the heels of this, in the third quarter, we engaged with the FDA in a Type B meeting to explore the potential of expanding the label to include infants less than 24 months of age. Based on the feedback, we expect to file an sNDA in the first quarter of 2027. Importantly, we believe MIPLYFFA is supported by a strong intellectual property portfolio.

Neil McFarlanePresident and CEO

MIPLYFFA is covered by patents listed in the Orange Book, with expiration dates extending to 2041, and has U.S. orphan drug exclusivity for the treatment of NPC through 2031. These provide distinct layers of protection, regulatory-based exclusivity, and listed patent coverage. As mentioned on previous calls, we are also pursuing a potential patent term extension through the U.S. Patent and Trademark Office, and based on the current processing times, we now anticipate a decision from the USPTO in 2027. In the E.U., the re-examination process for our Marketing Authorisation Application, or MAA, for arimoclomol is underway by the Committee for Medicinal Products for Human Use, or CHMP. As part of the re-examination, a new rapporteur and co-rapporteur have been appointed to lead the CHMP's evaluation. Additionally, an ad hoc expert group, or AHEG, will meet to review the data and provide their specialized scientific and clinical expertise.

Neil McFarlanePresident and CEO

This is an important forum for experts in the field to offer perspectives that will contribute to the CHMP's procedural discussions. We believe the totality of the clinical and real-world evidence supports the clinically meaningful benefits observed in patients treated with arimoclomol. The significant unmet need in Europe motivates us to keep working on behalf of people living with NPC, and we expect the CHMP's opinion in the fourth quarter. Due to the proximity of the AHEG and CHMP meetings, we will be brief in addressing questions regarding the ongoing procedure. Turning to our global expanded access program, or EAP, we remain steadfast in our commitment to the NPC community and supporting access to arimoclomol for eligible patients. Our global EAP has enrolled 134 patients and is comprised of compassionate use and named patient reimbursement programs.

Neil McFarlanePresident and CEO

As previously discussed, quarterly reimbursement amounts fluctuate based on the timing and cadence of orders. Of note, this past quarter, we expanded the program to include an additional territory and continue to evaluate more opportunities to expand access to patients globally. Moving to our late-stage pipeline, celiprolol is being evaluated for the treatment of vascular Ehlers-Danlos syndrome, or vEDS. vEDS is a rare inherited connective tissue disorder caused by a change in the COL3A1 gene, leading to fragile walls in blood vessels and hollow organs, which can cause arterial rupture or dissection, among other complications. With our phase III DiSCOVER trial, we are confirming the ability of celiprolol, our selective adrenoreceptor modulator, to reduce the mechanical stress on these tissues, thereby lowering the risk of major event. We enrolled six new patients in the third quarter for a total of 72.

Neil McFarlanePresident and CEO

As a reminder, the trial was designed with an interim analysis triggered at 28 events, and there have been four confirmed events through the end of Q3. We have discussed previously that we are focused on advancing the ongoing DiSCOVER trial and are exploring options to accelerate the program by engaging with the FDA. Following a Type C meeting in the first quarter, we recently held a second Type C meeting to discuss a potential submission strategy with the addition of real-world data sets. While we await formal meeting minutes to confirm next steps, we are developing a statistical analysis plan to include the retrospective data sets with the intent to have a follow-up discussion with the agency in the first half of 2027. Across our business, we remain focused on advancing key opportunities while maintaining a strong financial position.

Neil McFarlanePresident and CEO

With more than $270 million in cash equivalents, and investments as of the end of Q3, we believe we have the flexibility to pursue near-term opportunities with MIPLYFFA in the U.S. and broadening access for patients in global markets, as well as advancing our development pipeline. I will now ask Josh to review our commercial momentum.

Josh SchaferChief Commercial Officer

Josh? Thank you, Neil. We continue to build the foundation for sustained MIPLYFFA growth through patient identification, disease awareness, and stakeholder engagement.

Josh SchaferChief Commercial Officer

Our progress is reflected not only in the 197 prescription enrollment forms submitted since launch, but also in our broader activity and growing awareness across the NPC community. In the third quarter, the 13 prescription enrollment forms we received included a balance of adult and pediatric patients, as well as a meaningful proportion of newly diagnosed patients. As a reminder, NPC is a fatal lysosomal storage disorder leading to abnormal lipid accumulation, which over time causes progressive dysfunction of the nerves, brain, and other organs. This results in neurodegenerative and visceral symptoms, including negative impacts on speech, cognitive function, fine motor skills, and the ability to swallow.

Josh SchaferChief Commercial Officer

The symptoms are variable across patients, and many people with NPC experience a prolonged period before diagnosis due to the lack of disease awareness. Disease progression is irreversible and varies based on the age of symptom onset. MIPLYFFA, in combination with miglustat, has been established as a foundational treatment for NPC and has demonstrated a halting of disease progression at 12 months and rapid improvement by the first assessment at week 12 based on NPC Clinical Severity Scale. This is further reinforced by the recently published clinical practice guidelines, as well as real-world evidence confirming MIPLYFFA's long-term efficacy and safety profile. We published new data in the third quarter, and at the recent SSIEM annual symposium, findings were presented from our early access programs showing sustained disease stabilization across age groups, including adults.

Josh SchaferChief Commercial Officer

Since launch, we have observed high patient retention and refill rates, consistent with what we observed in our EAP study. This data helps support our market access position and payer coverage, which is currently 69%. The majority of remaining patients receive coverage through medical exception pathways. This broad coverage is facilitated through our ongoing dialogues and engagement with payers, including regular presentations and conference participation. Our integrated commercial strategy is focused on identifying new patients, accelerating their diagnosis, and expanding access to treatment. Because NPC symptoms vary widely, the disease can be difficult to diagnose. We support overall disease awareness with our campaign called Learn NPC, Read Between the Signs. We also support early diagnosis through collaborations with genetic testing providers.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day